A biologic therapy used to treat metastatic breast cancer in patients whose cancers are positive for the human epidermal growth factor-2 (HER-2).
Generic name for Herceptin
(tras-TOO-zuh-mab) A monoclonal antibody used to treat breast cancer that is estrogen-receptor positive and has spread after treatment with other drugs. It is also being studied in the treatment of other types of cancer. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Trastuzumab binds to HER-2, a human epidermal growth factor receptor, and can kill HER-2 positive cancer cells. Also called Herceptin.
A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells. Trastuzumab blocks the effects of the growth factor protein HER2 which transmits growth
(brand name, Herceptin): See Herceptin.
(tras-TOO-zuh-mab) A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor), and can kill HER2-positive cancer cells. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Trastuzumab is used to treat breast cancer that is HER2-positive and has spread after treatment with other drugs. It is also used with other anticancer drugs to treat HER2-positive breast cancer after surgery. Trastuzumab is also being studied in the treatment of other types of cancer. Also called Herceptin.
An anticancer drug that belongs to a group of highly specific protein substances called monoclonal antibodies. It blocks the effects of the growth factor protein HER2 which transmits growth signals to breast cancer cells.
a type of monoclonal antibody which blocks the effects of the growth factor protein HER2, which transmits growth signals to cancer cells
Trastuzumab (more commonly known under the trade name Herceptin) is a humanized monoclonal antibody that acts on the HER2/neu (erbB2) receptor. Herceptin's principal use is as an anti-cancer therapy in breast cancer in patients whose tumors overexpress (produce more than the usual amount of) this receptor. Trastuzumab is administered either once a week or once every three weeks intravenously for 30 to 90 minutes.
